History

Background theory People with (T2DM) typically have a condition known as chronic kidney disease (CKD).As a result, one of the complications that led to morbidity, mortality, and patients staying in the hospital for an extended period of time. Fetuin-B is a new cytokine that is synthesized and released from the liver in various diseases as a marker for progression outcomes. In the past several years, (T2DM) and (CKD) have been linked (T2DM). As fetuin-B may be a marker for the early diagnosis of chronic kidney disease (CKD) in people with diabetic nephropathy, the goal of this study was to measure serum levels of this protein in adults with type 2 diabetes. Subject and Procedure: We used (ELISA) to evaluate the planes of serum fetuin-B in a case-control research involving 61 patients with T2DM, 20 of whom had complications like diabetic nephropathy, and 19 participants who appeared to be in good condition. In addition, all participants had their biochemistry and HbA1c markers estimated. As a result, patients with CKD had significantly greater blood concentrations of Fetuin-B compared to those with T2DM (p-value 0.001), and those with T2DM had higher serum concentrations compared to those with control diabetes (p-value 0.001) are also closely related to gender, (BMI), fasting blood sugar (HbA1c), lipid profile, liver enzyme (ALT, AST), and the presence of inflammation. Serum fetuin-B concentrations can aid in the early identification of diabetic nephropathy and may also be useful in assisting type 2 diabetics in predicting the onset of chronic kidney disease (CKD).